Cantor Fitzgerald Weighs in on Verastem FY2025 Earnings

Verastem, Inc. (NASDAQ:VSTM) – Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Verastem in a note issued to investors on Thursday, October 30th. Cantor Fitzgerald analyst E. Schmidt forecasts that the biopharmaceutical company will post earnings of ($2.60) per share for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Verastem’s current full-year earnings is ($3.02) per share. Cantor Fitzgerald also issued estimates for Verastem’s FY2026 earnings at ($2.06) EPS.

Verastem (NASDAQ:VSTM) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.25. The business had revenue of $2.14 million during the quarter, compared to the consensus estimate of $6.01 million.

VSTM has been the topic of several other reports. B. Riley upgraded Verastem to a “strong-buy” rating in a report on Monday, August 25th. BTIG Research restated a “buy” rating and set a $20.00 price target on shares of Verastem in a report on Tuesday, September 9th. Royal Bank Of Canada set a $13.00 price target on Verastem and gave the stock an “outperform” rating in a report on Monday, October 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Verastem in a report on Wednesday, October 8th. Finally, Mizuho set a $15.00 target price on Verastem in a report on Wednesday. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $14.29.

Verastem Stock Performance

NASDAQ:VSTM opened at $9.45 on Monday. The stock has a market cap of $581.55 million, a P/E ratio of -2.88 and a beta of 0.89. The company has a current ratio of 3.46, a quick ratio of 3.44 and a debt-to-equity ratio of 2.06. The stock’s 50-day moving average is $9.10 and its 200-day moving average is $7.31. Verastem has a 1-year low of $3.45 and a 1-year high of $11.24.

Institutional Investors Weigh In On Verastem

Institutional investors and hedge funds have recently bought and sold shares of the stock. E Fund Management Co. Ltd. purchased a new stake in Verastem in the 2nd quarter valued at $49,000. Nebula Research & Development LLC bought a new position in Verastem in the 2nd quarter valued at $53,000. The Manufacturers Life Insurance Company grew its stake in Verastem by 9.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 16,188 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 1,440 shares during the period. Profund Advisors LLC bought a new position in Verastem in the 2nd quarter valued at $90,000. Finally, Los Angeles Capital Management LLC bought a new position in Verastem in the 2nd quarter valued at $106,000. 88.37% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Verastem

In other news, Director Paul A. Bunn sold 8,333 shares of the company’s stock in a transaction that occurred on Thursday, October 9th. The stock was sold at an average price of $9.06, for a total transaction of $75,496.98. Following the transaction, the director directly owned 8,333 shares of the company’s stock, valued at $75,496.98. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 11,005 shares of company stock worth $96,552 over the last quarter. 2.10% of the stock is owned by corporate insiders.

About Verastem

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.